Categories AlphaGraphs, Earnings, Health Care

Eli Lilly’s stock down after Q1 revenues miss forecasts

Eli Lilly and Company (NYSE: LLY) surpassed analysts’ expectations on earnings for the first quarter of 2019 while revenues fell short of estimates. Shares were down 3.4% in morning hours on Tuesday.

Worldwide revenue increased 3% year-over-year to $5 billion, helped by a 7% increase in volume.

Eli Lilly reports Q1 2019 earnings results

Net income improved to $4.2 billion, or $4.31 per share, compared to $1.2 billion, or $1.16 per share in the year-ago quarter, helped by a gain recognized on the disposition of Elanco Animal Health. Adjusted net income fell 4% to $1.2 billion while adjusted EPS rose 2% to $1.33.

Revenue in the US grew 3% year-over-year to $2.8 billion, driven by a volume increase of 6%. Revenue outside the US rose 2% to $2.2 billion, helped by a volume growth of 9%. Volume growth, both in the US and internationally, were driven by key products like Trulicity and Taltz.

Products such as Trulicity, Taltz, Basaglar and Jardiance posted double-digit revenue growth during the quarter helped by higher demand and volume growth. Products like Cialis, Humalog and Humulin posted sales declines hurt by factors like generic competition and foreign exchange rate fluctuations.

Eli Lilly updated its guidance to reflect the disposition of the Elanco Animal Health business. For the full year of 2019, the company lowered its revenue outlook to a range of between $22 billion and $22.5 billion. The company increased its earnings guidance and now expects GAAP EPS to be $8.57-8.67 and adjusted EPS to be $5.60-5.70.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Also Read:  Infographic: Chewy (CHWY) Q2 2020 earnings in a nutshell

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results

Top